Hidradenitis Suppurativa – Opportunity Analysis and Forecasts to 2028

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hidradenitis Suppurativa: Executive Summary

2.1 New Entrants Will Drive Modest Growth Across the 7MM from 2018 to 2028

2.2 Launch of Pipeline Therapies Will Lead to Change in the HS Landscape

2.3 High Unmet Needs Exists in the HS Market, Especially for a Highly Efficacious Treatment

2.4 Pipeline Agents Will Offer Incremental Improvements Over Current Therapies

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for HS (2018–2028)

5.5.1 Diagnosed Active Prevalent Cases of HS

5.5.2 Age-Specific Diagnosed Active Prevalent Cases of HS

5.5.3 Sex-Specific Diagnosed Active Prevalent Cases of HS

5.5.4 Diagnosed Active Prevalent Case of HS by Severity

5.5.5 Diagnosed Active Prevalent Cases of HS with IBD

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis

6.3 Treatment

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Efficacious Treatment

7.3 Early Diagnosis of HS

7.4 Lack of Treatment Options for Fibrosis

7.5 Lack of Holistic Management of HS

8 R&D Strategies

8.1 Overview

8.1.1 Biological Therapies

8.1.2 Oral Therapies

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Design

8.2.2 Limitations and Future Outlook

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.4.1 KOLs

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Managing Epidemiologist

11.6.4 Global Director of Therapy Analysis and Epidemiology

11.6.5 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table 1: Hidradenitis Suppurativa: Key Metrics in the 7MM

Table 2: Classification of Hidradenitis Suppurativa

Table 3: Risk Factors and Comorbidities for Hidradenitis Suppurativa

Table 4: Treatment Guidelines for HS

Table 5: Leading Treatments for Hidradenitis Suppurativa, 2019

Table 6: Clinical Trial Design for HS Pipeline Agents in Late-Stage Development, 2018

Table 7: Innovative Early-Stage Approaches for Hidradenitis Suppurativa, 2018

Table 8: Clinical Benchmark of Key Pipeline Drugs – HS, 2018

Table 9: Commercial Benchmark of Key Pipeline Drugs – Hidradenitis Suppurativa, 2018

Table 10: Key Events Impacting Sales for HS, 2018–2028

Table 11: Hidradenitis Suppurativa Market – Global Drivers and Barriers, 2018–2028.

Table 12: Key Historical and Projected Launch Dates for HS

Table 13: Key Historical and Projected Patent Expiry Dates for HS

Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for HS in 2018 and 2028

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira

Figure 3: Pathophysiology of Hidradenitis Suppurativa

Figure 4: Diagnosed Active Prevalence of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, (%)

Figure 5: Sources Used and Not Used for Diagnosed Active Prevalence of HS

Figure 6: Sources Used for Severity of HS

Figure 7: Sources Used for Digestive Comorbidities of HS

Figure 8: Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N

Figure 9: Age-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N

Figure 10: Sex-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men, Women, Ages ≥18 Years, 2018, N

Figure 11: Diagnosed Active Prevalent Cases of HS by Severity, 7MM, Men and Women, Ages ≥18 Years, 2018, N

Figure 12: Diagnosed Active Prevalent Cases of HS with IBD, 7MM, Men and Women, Ages ≥18 Years, 2018, N

Figure 13: Treatment Algorithm for HS

Figure 14: Unmet Needs and Opportunities in Hidradenitis Suppurativa

Figure 15: Overview of the Development Pipeline in HS

Figure 16: 7MM, Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Launched for HS During the Forecast Period

Figure 17: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira

Figure 18: Global (7MM) Sales Forecast, by Country, for HS in 2018 and 2028

Figure 19: Global Sales Forecast by Class for HS in 2018 and 2028

Figure 20: Sales Forecast by Class for HS in the US in 2018 and 2028

Figure 21: Sales Forecast by Class for HS in the 5EU in 2018 and 2028

Figure 22: Sales Forecast by Class for HS in Japan in 2018 and 2028